Summit Therapeutics

Summit Therapeutics

Yahoo Finance • 3 days ago

Notable healthcare headlines for the week: Novo Nordisk, GE HealthCare, and Eli Lilly in focus

Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-n... Full story

Yahoo Finance • 9 days ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 10 days ago

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is Conducting Global Phase... Full story

Yahoo Finance • 14 days ago

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compil... Full story

Yahoo Finance • 20 days ago

Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. Continue Reading... Full story

Yahoo Finance • 20 days ago

Summit Therapeutics in focus as its lung cancer drug shows survival benefit

* Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) said on Wednesday that partner Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]) reported positive overall survival results [https://seekingalpha.com/pr/20639170-ivo... Full story

Yahoo Finance • 21 days ago

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC MIAMI, September 02, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (O... Full story

Yahoo Finance • 21 days ago

Ten healthcare stocks leading in year-over-year CapEx growth

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthca... Full story

Yahoo Finance • 27 days ago

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer

Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.... Full story

Yahoo Finance • 27 days ago

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Shares of Summit Therapeutics SMMT rose 6.5% on Wednesday after the company's partner Akeso announced positive top-line results from the phase III HARMONi-GI1 study conducted in China in certain patients with biliary tract cancer (BTC). T... Full story

Yahoo Finance • 28 days ago

Sector Update: Healthcare Stocks Fall Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 29 days ago

Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade

Researcher looking through microscope ©Adobe Stock Images Summit Therapeutics (NASDAQ:SMMT) shares gained 1.1% in pre-market trading after Bernstein SocGen upgraded the biotechnology company to Market Perform from Underperform and raised... Full story

Yahoo Finance • last month

Summit higher as partner Akeso wins China label expansion for lead drug

[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansi... Full story

Yahoo Finance • 2 months ago

At a glance: stocks gapping down premarket

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Friday. Stock index futures were higher on Friday as the stock market hoped to recover from Thursday's s... Full story

Yahoo Finance • 2 months ago

After-Hours Earnings Report for July 23, 2026 : INTC, NEM, FIX, DLR, EW, HIG, VRSN, OVV, SSNC, DECK, SMMT, SSB

The following companies are expected to report earnings after hours on 07/23/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Intel Corporation (INTC)is reporting for the quarter ending June 30, 2026. Th... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Intel Corporation (INTC [https://seekingalpha.com/symbol/INTC]) * Newmont Corporation (NEM [https://seekingalpha.com/symbol/NEM]) * Digital Realty Trust (DLR [https://see... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story

Yahoo Finance • 3 months ago

The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution

DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and ch... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Summit Therapeutics Inc. (NASDAQ:SMMT) withdrew a $500 million proposed underwritten public offering it ha... Full story

Yahoo Finance • 3 months ago

Summit rebounds after nearly $50M insider purchase

[$10 Banknote Stacking, Green Up Arrow Rise] spawns * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) bounced back, recovering recent losses on Friday after the cancer drug developer’s co-CEO Robert Duggan di... Full story